Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Novartis
Moodys
Teva
McKinsey
Medtronic
Chinese Patent Office
Express Scripts
Colorcon
Healthtrust

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,017,721

« Back to Dashboard

Which drugs does patent 9,017,721 protect, and when does it expire?

Patent 9,017,721 protects ZORVOLEX and is included in one NDA.

This patent has thirty-nine patent family members in twenty-two countries.
Summary for Patent: 9,017,721
Title:Formulation of diclofenac
Abstract: The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.
Inventor(s): Dodd; Aaron (Centennial Park, AU), Meiser; Felix (Mount Claremont, AU), Norret; Marck (Darlington, AU), Russell; Adrian (Rivervale, AU), Bosch; H William (Bryn Mawr, PA)
Assignee: iCeutica Pty Ltd. (Philadelphia, PA)
Application Number:14/277,287
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,017,721

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Iroko Pharms Llc ZORVOLEX diclofenac CAPSULE;ORAL 204592-001 Oct 18, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Iroko Pharms Llc ZORVOLEX diclofenac CAPSULE;ORAL 204592-002 Oct 18, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,017,721

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Australia2009901748Apr 24, 2009

Non-Orange Book US Patents Family Members for Patent 9,017,721

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,180,095 Formulation of diclofenac ➤ Subscribe
8,679,544 Formulation of diclofenac ➤ Subscribe
8,735,450 Formulation of diclofenac ➤ Subscribe
9,180,096 Formulation of diclofenac ➤ Subscribe
9,173,854 Formulation of diclofenac ➤ Subscribe
8,999,387 Formulation of diclofenac ➤ Subscribe
9,186,328 Formulation of diclofenac ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,017,721

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 3774 ➤ Subscribe
Australia 2010239080 ➤ Subscribe
Australia 2014208310 ➤ Subscribe
Brazil PI1014272 ➤ Subscribe
Canada 2759123 ➤ Subscribe
China 102438610 ➤ Subscribe
China 104161743 ➤ Subscribe
China 106420667 ➤ Subscribe
China 106727424 ➤ Subscribe
China 106727477 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Federal Trade Commission
Moodys
Accenture
Chinese Patent Office
QuintilesIMS
Julphar
UBS
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot